Log in or Sign up for Free to view tailored content for your specialty!
Oncology News
HCC risk low among patients with cirrhosis
The risk for hepatocellular carcinoma was low among patients with cirrhosis, with a 10-year incidence of 4% or lower, according to the results of a U.K. population-based cohort study.
Stivarga improves OS for unresectable HCC
Stivarga was safe and improved overall survival for patients with unresectable hepatocellular carcinoma, according to data from the RESORCE clinical trial recently published in The Lancet.
Log in or Sign up for Free to view tailored content for your specialty!
FDA grants orphan drug designation to protein kinase CK2 inhibitor for cholangiocarcinoma
The FDA has issued orphan drug designation to CX-4945 for the treatment of cholangiocarcinoma, which will expedite its development, the manufacturer announced.
FDA grants priority review to Stivarga for second-line treatment of HCC
The FDA granted priority review to regorafenib tablets as a second-line systemic treatment for patients with hepatocellular carcinoma, according to the drug’s manufacturer.
HCC most common indication for LT, waitlist placement in US
In 2015, hepatocellular carcinoma was the most common indication for liver transplantation in the U.S., yet the likelihood of receiving a transplantation decreased the most among waitlist registrants with this cancer, according to recent study data.
Rising HCC incidence slowing in US, except in certain subgroups
Although the incidence of hepatocellular carcinoma continued to rise, researchers discovered the rate of increase slowed between 2010 and 2012, except among high risk subgroups in certain geographic regions.
Y90 radioembolization delays time to HCC progression vs. TACE
In a phase 2 clinical trial, the use of yttrium-90 radioembolization was more effective in prolonging time to tumor progression vs. conventional transarterial chemoembolization in patients with early intermediate hepatocellular carcinoma.
Medicare beneficiaries without supplemental insurance hit hardest by cancer costs
Medicare beneficiaries who are diagnosed with cancer and are without supplemental health insurance incurred out-of-pocket expenses of nearly a quarter of their household income, according to a national survey-based study published in JAMA Oncology.
SVR post–interferon-based therapy reduces, not eliminates risk for HCC
Researchers found through long-term follow-up that patients with hepatitis C virus infection who achieved sustained virologic response after interferon-based therapy were still at risk for hepatocellular carcinoma, more specifically older patients and those with cirrhosis.
FDA grants 510(k) clearance to new ultrasound modes for liver, breast imaging
SuperSonic Imagine announced the FDA granted 510(k) clearance to add additional imaging probes — for liver disease and breast lesions — for use with its Aixplorer platform.
-
Headline News
We must make our voices heard and vote in the 2024 election
September 18, 20247 min read -
Headline News
Semaglutide improves glucose control in automated insulin delivery for type 1 diabetes
September 20, 20243 min read -
Headline News
Oncologists, primary care clinicians should be aware of BRCA testing indications in men
September 19, 20244 min read
-
Headline News
We must make our voices heard and vote in the 2024 election
September 18, 20247 min read -
Headline News
Semaglutide improves glucose control in automated insulin delivery for type 1 diabetes
September 20, 20243 min read -
Headline News
Oncologists, primary care clinicians should be aware of BRCA testing indications in men
September 19, 20244 min read